Prevention of Epstein-Barr virus–lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantationJoost W. J. van Esser, Jan J. Cornelissen|Blood|2002Cited by 401
Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patientsAlexandros Spyridonidis, Mohamad Mohty, Florent Malard et al.|Bone Marrow Transplantation|2020Cited by 202
Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMTMohamad Mohty, Jaime Sanz, Jacques‐Emmanuel Galimard et al.|Journal of Hematology & Oncology|2020Cited by 117
Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantationJan Moritz Middeke, Johannes Schetelig, Min Fang et al.|Blood|2014Cited by 74
Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donorsÉolia Brissot, Mohamad Mohty, Myriam Labopin et al.|Journal of Hematology & Oncology|2020Cited by 68